anastrozole has been researched along with Dwarfism in 2 studies
Dwarfism: A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shams, K | 1 |
| Cameo, T | 1 |
| Fennoy, I | 1 |
| Hassoun, AA | 1 |
| Lerner, SE | 1 |
| Aranoff, GS | 1 |
| Sopher, AB | 1 |
| Yang, C | 1 |
| McMahon, DJ | 1 |
| Oberfield, SE | 1 |
| Mauras, N | 1 |
| Ross, JL | 1 |
| Gagliardi, P | 1 |
| Yu, YM | 1 |
| Hossain, J | 1 |
| Permuy, J | 1 |
| Damaso, L | 1 |
| Merinbaum, D | 1 |
| Singh, RJ | 1 |
| Gaete, X | 1 |
| Mericq, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial Of The Use Of Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature[NCT01248416] | Phase 3 | 76 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01248416)
Timeframe: 0 to 24 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aromatase Inhibitor | 2.5 |
| Growth Hormone | 1.7 |
| Aromatase Inhibitor and Growth Hormone | 2.5 |
(NCT01248416)
Timeframe: 0 to 24 months
| Intervention | z-score (Least Squares Mean) |
|---|---|
| Aromatase Inhibitor | -1.061 |
| Growth Hormone | -0.586 |
| Aromatase Inhibitor and Growth Hormone | -0.605 |
Those taking AI alone or AI/GH combined were grouped by type, either anastrozole or letrozole. (NCT01248416)
Timeframe: 0 to 24 months
| Intervention | pg/mL (Mean) |
|---|---|
| Anastrozole | 8 |
| Letrozole | 4 |
(NCT01248416)
Timeframe: 0 to 24 months
| Intervention | pg/mL (Mean) |
|---|---|
| Aromatase Inhibitor | 0.0 |
| Growth Hormone | 6.1 |
| Aromatase Inhibitor and Growth Hormone | -0.9 |
Differences in height gains (NCT01248416)
Timeframe: 0 to 24 months
| Intervention | Centimeters (Mean) |
|---|---|
| Aromatase Inhibitor | 14 |
| Growth Hormone | 17.1 |
| Aromatase Inhibitor and Growth Hormone | 18.9 |
(NCT01248416)
Timeframe: 0 to 24 months
| Intervention | ng/mL (Mean) |
|---|---|
| Aromatase Inhibitor | 158 |
| Growth Hormone | 280 |
| Aromatase Inhibitor and Growth Hormone | 303 |
(NCT01248416)
Timeframe: 0 to 24 months
| Intervention | kg (Mean) |
|---|---|
| Aromatase Inhibitor | 42.2 |
| Growth Hormone | 42.0 |
| Aromatase Inhibitor and Growth Hormone | 46.5 |
Primary efficacy end point: change in predicted height (cm) from baseline at 24 months based on change in bone age (years) (NCT01248416)
Timeframe: 0 to 24 months
| Intervention | centimeters (Least Squares Mean) |
|---|---|
| Aromatase Inhibitor | 0.5 |
| Growth Hormone | 4.9 |
| Aromatase Inhibitor and Growth Hormone | 7.4 |
(NCT01248416)
Timeframe: 0 to 24 months
| Intervention | ng/dL (Mean) |
|---|---|
| Aromatase Inhibitor | 737 |
| Growth Hormone | 372 |
| Aromatase Inhibitor and Growth Hormone | 668 |
1 trial available for anastrozole and Dwarfism
| Article | Year |
|---|---|
Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature.
Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Body Composition; Body Height; Drug Therapy, Combinat | 2016 |
1 other study available for anastrozole and Dwarfism
| Article | Year |
|---|---|
Outcome analysis of aromatase inhibitor therapy to increase adult height in males with predicted short adult stature and/or rapid pubertal progress: a retrospective chart review.
Topics: Adolescent; Adult; Age Determination by Skeleton; Anastrozole; Aromatase Inhibitors; Body Height; Bo | 2014 |